loading...| Preferred Name |
Dasatinib |
|
| Synonyms |
Dasatinib Hydrate 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate Dasatinib Monohydrate BMS-354825 DASATINIB Dasatinib Sprycel dasatinib |
|
| Definitions |
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C38713 |
|
| Accepted_Therapeutic_Use_For |
Chronic myeloid leukemia; Philadelphia chromosome-positive acute lymphoblastic leukemia |
|
| ALT_DEFINITION |
A drug used to treat certain types of chronic myeloid leukemia and acute lymphoblastic leukemia. BMS-354825 is also being studied in the treatment of certain other blood diseases and types of cancer. BMS-354825 binds to and blocks BCR-ABL and other proteins that help cancer cells grow. It is a type of tyrosine kinase inhibitor. |
|
| CAS_Registry |
863127-77-9 |
|
| Chemical_Formula |
C22H26ClN7O2S.H2O |
|
| code |
C38713 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. |
|
| Display_Name |
Dasatinib |
|
| FDA_UNII_Code |
RBZ1571X5H |
|
| FULL_SYN |
Dasatinib Hydrate 5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)-, Monohydrate Dasatinib Monohydrate BMS-354825 DASATINIB Dasatinib Sprycel dasatinib |
|
| Has_Target |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C30164 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16325 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17328 |
|
| Is_Value_For_GDC_Property | ||
| label |
Dasatinib |
|
| Legacy Concept Name |
BMS-354825 |
|
| Maps_To |
Dasatinib |
|
| NCI_Drug_Dictionary_ID |
315885 |
|
| NSC Number |
732517 |
|
| PDQ_Closed_Trial_Search_ID |
315885 |
|
| PDQ_Open_Trial_Search_ID |
315885 |
|
| Preferred_Name |
Dasatinib |
|
| prefixIRI |
Thesaurus:C38713 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C1455147 |
|
| subClassOf |